Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone plus low-dose dextromethorphan in idiopathic pulmonary fibrosis
ChiCTR2000037602Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pirfenidone and dextromethorphan in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Chest HRCT and Pulmonary function. Started Sep 2019; status: recruiting.
02
Drugs
pirfenidonedextromethorphan
03
Conditions
idiopathic pulmonary fibrosis (IPF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on ChiCTR2000037602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037602.